Patents by Inventor Haishan ZANG

Haishan ZANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID PHARMACEUTICAL COMPOSITION COMPRISING TLR7 AGONIST
    Publication number: 20220184085
    Abstract: A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties.
    Type: Application
    Filed: April 23, 2020
    Publication date: June 16, 2022
    Inventors: Jianghui Jing, Lihui Dong, Yi Xu, Xinlu Li, Xifeng Lu, Shang Wang, Haishan Zang, Min Li, Zhilin Chen, Xiandong Zhao, Peng Sun
  • Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof
    Patent number: 11279676
    Abstract: The present application falls within the field of medicinal chemistry, relates to the crystalline of a compound as a c-Met kinase inhibitor, and specifically relates to the crystalline of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystalline for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystalline of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 22, 2022
    Inventors: Feng Gong, Ticong Huang, Haishan Zang, Shibo Zhang, Rui Zhao, Fei Liu
  • CRYSTALLINE OF COMPOUND AS C-MET KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20210047272
    Abstract: The present application falls within the field of medicinal chemistry, relates to the crystalline of a compound as a c-Met kinase inhibitor, and specifically relates to the crystalline of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystalline for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystalline of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.
    Type: Application
    Filed: March 1, 2019
    Publication date: February 18, 2021
    Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Advenchen Laboratories Nanjing Ltd.
    Inventors: Feng GONG, Ticong HUANG, Haishan ZANG, Shibo ZHANG, Rui ZHAO, Fei LIU